Stem Cell Clinic

Wyatt-MacKenzie Spring 2015 An Illustrated Biography of Jane Austen and Two Health-Related Re-Releases on Getting …

By Stem Cell Doctors

Deadwood, OR (PRWEB) April 04, 2015

New 2015 Release

What was Jane Austen like as a child? What inspired her to write?

Young Jane Austen: Becoming a Writer is a colorful new biography with a special focus on Austens creative development during her childhood and the connections to her work as a mature writer. Drawing upon a wide array of sources, including Austens own books and correspondence, author Lisa Pliscou illuminates the life of the youthful Jane and the fascinating connections to her much-loved writing. Lavishly annotated, designed with an evocative antique sensibility, and featuring 20 specially commissioned illustrations, Young Jane Austen is sure to intrigue anyone interested in Jane Austen, her enduring legacy, and the triumph of the artistic spirit.

It is adorable, raved The NYC Jane Austen Society upon receiving an advance review copy. Like the very best of books, Young Jane Austen exists well beyond labels. It is an empathetic biography and an empathic search, a reflection on a singular person and an engaging, universal treatise on creative fervor, reviews Beth Kephart, author of Handling the Truth: On the Writing of Memoir and Going Over.

Young Jane Austen is described eloquently by Jane Odiwe, author of Searching for Captain Wentworth and Lydia Bennets Story: A delightful glimpse into the world of the young Jane Austen, which will appeal to adults as well as teenagers. The narrative is beautifully written, enabling the reader to vividly imagine Janes world of family, events, and her inner life, on the journey to becoming a writer during her formative years. The addition of annotations and reference material, gained from many sources, help further explore the historical background and context, along with accompanying illustrations, setting Jane Austen firmly in the Georgian world. A charming tribute.

Author Lisa Pliscou will be the keynote speaker at a meeting of the Jane Austen Society of Northern California, celebrating Austens birthday in December. Young Jane Austen will be available via the Jane Austen Centre in Bath, England, as well as through other venues in Bath, and featured at various Jane Austen festivals both in the U.S. and around the world. Learn more at LisaPliscou.com.

Wyatt-MacKenzie Re-Releases

Sandi Selvi proves laughter is good medicine, and that a stem cell transplant can cure MS. Matt Bellace reveals scientifically proven natural highs.

A Stem Cell Transplant MS Recovery Story: Beating Multiple Sclerosis with Humor, Hope & Science originally titled Wont Do Stand-Up in a Wheelchair was re-released with an addendum for the authors 15th anniversary of her successful stem cell transplant. After being diagnosed with MS in 1995, Sandi Selvi began to decline rapidly and quickly became frustrated with conventional medical options. In March of 2000 Sandi joined forces with the brilliant doctors at Scripps in San Diego for a $100,000 autologous stem cell transplant. During the two-month medical procedure Sandi came pretty close to death, but a $10.99 box of comedy tapes helped her through recovery, and changed her life.

Read the original post:
Wyatt-MacKenzie Spring 2015 An Illustrated Biography of Jane Austen and Two Health-Related Re-Releases on Getting ...

Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D. – Video

By Uncategorized


Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D.
Bill describes his result one year after bone marrow stem cell therapy by Dr. Harry Adelson for low back pain caused by a degenerated and herniated lumbar disc.

By: Harry Adelson, N.D.

View post:
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D. - Video

Trinity Spine and Wellness Center Reviews – Stem Cell Treatment Tampa – Video

By Stem Cell Treatment


Trinity Spine and Wellness Center Reviews - Stem Cell Treatment Tampa
http://Trinity-Spine.com (727) 372-9922 Trinity Spine and Wellness Center Odessa review By Brian F. 5 Star Rating Dr. Hayes and his entire staff are awesome! I #39;ve had a couple of back surgeries...

By: Anderson Flanders

Read the original here:
Trinity Spine and Wellness Center Reviews - Stem Cell Treatment Tampa - Video

Stem cell implant shows promise for Parkinson's treatment

By Stem Cell Treatment

New York, April 4 (IANS): An implant of stem cells treated with an anti-cancer drug has been found to be effective against Parkinson's symptoms in mice.

The findings published in the journal Frontiers in Cellular Neuroscience could be an important step toward using the implantation of stem cell-generated neurons as a treatment for Parkinson's disease in humans.

Using a US Food and Drug Administration (FDA)-approved anti-cancer drug, the researchers were able to grow dopamine-producing neurons derived from embryonic stem cells that remained healthy and functional for as long as 15 months after implantation into mice, restoring motor function without forming tumours.

"This simple strategy of shortly exposing pluripotent stem cells to an anti-cancer drug turned the transplant safer, by eliminating the risk of tumour formation", said the leader of the study Stevens Rehen, professor at the Federal University of Rio de Janeiro (UFRJ) in Brazil.

Parkinson's, which affects as many as 10 million people in the world, is caused by a depletion of dopamine-producing neurons in the brain.

Several studies have indicated that the transplantation of embryonic stem cells improves motor functions in animal models. However, until now, the procedure was shown to be unsafe because of the risk of tumours upon transplantation.

To address this issue, the researchers for the first time pre-treated undifferentiated mouse embryonic stem cells with mitomycin C, a drug already prescribed to treat cancer.

The substance blocks the DNA replication and prevents the cells from multiplying out of control.

The researchers used mice modelled for Parkinson's. Unlike the control group, animals receiving the treated stem cells showed improvement in Parkinson's symptoms and survived until the end of the observation period of 12 weeks post-transplant with no tumours detected.

Four of these mice were monitored for as long as 15 months with no signs of pathology.

Read more:
Stem cell implant shows promise for Parkinson's treatment

Is a loophole in stem cell law helping new therapy to thrive, or allowing dubious science?

By Stem Cell Treatment

Life-changing results: Sandra Sharman is a private stem cell patient. Photo: Meredith O'Shea

Last week, Suzie Palmer, 44, travelled from her home in NSW to the Gold Coast for her second round of stem cell treatments for multiple sclerosis. OnTuesday morning,the wheelchair-bound poet underwent liposuction.

By 2.30pm, stem cells had been partially separated from her abdominal fat, suspended in plasma, and injected intravenously. Her doctor, Soraya Felix, is a cosmetic surgeon and molecular biologist with a sideline in regenerative medicine.

Palmer, a relentlessly upbeat and positive person, says the treatments have helped her cope better with heat, improved her mobility and flexibility and otherwise made her "feel like a normal human being". She has, she says, managed a few steps with a walker, still a long way from "running about, which is my dream".

Poster girl: Suzie Palmer is undergoing stem cell therapy for MS. Photo: Edwina Pickles

The rapidly growing stem cell industry is aglow with similarly positive testimonials, notably on behalf of practitioners who offer little documented scientific evidence of their success.

Advertisement

Suzie Palmer is literally the poster girl for stem cell tourism within Australia. You can find her smiling sweetly, along with Dr Felix, on the Facebook page of a group called the Adult Stem Cell Foundation. She is one of an unknown number of unwell Australians pinning their hopes on an unregulated industry that is now under review by the Therapeutic Goods Administration.

The TGA public consultation, which closed earlier this month, was prompted by long-standing concerns raised by Stem Cells Australia that a loophole in the regulations has allowed dozens of doctors across Australia to provide experimental treatments without the ethics committee oversight that registered clinical trials are subject to. These treatments invariably cost $10,000 and up. The loophole is this: while the use of donor stem cells in therapies is tightly regulated, the use of a patient's own stem cells is not.

Professor Martin Pera is the program leader of Stem Cells Australia, which is administered by the University of Melbourne and includes scientists from Monash University, the Walter and Eliza Hall Institute for Medical Research, the Florey Institute and the CSIRO, among others. They are engaged in a seven-year Australian Research Council project to answer the big questions about stem cells and the potential for reliable therapies.

Here is the original post:
Is a loophole in stem cell law helping new therapy to thrive, or allowing dubious science?

Stem cell procedures for paralysis patients

By Stem Cell Doctors

According to the Christopher and Dana Reeve Foundation, nearly one in 50 people are living with paralysis.

Until now, there wasn't much hope.

But, a new study involving stem cells has doctors and patients excited.

Two years ago, Brenda Guerra's life changed forever.

"They told me that I went into a ditch and was ejected out of the vehicle," says Brenda.

The accident left the 26-year-old paralyzed from the waist down and confined to a wheelchair.

"I don't feel any of my lower body at all," says Brenda.

Brenda has traveled from Kansas to UC San Diego to be the first patient to participate in a ground-breaking safety trial, testing stem cells for paralysis.

"We are directly injecting the stem cells into the spine," says Dr. Joseph Ciacci, a neurosurgeon at UC San Diego.

The stem cells come from fetal spinal cords. The idea is when they're transplanted they will develop into new neurons and bridge the gap created by the injury by replacing severed or lost nerve connections. They did that in animals and doctors are hoping for similar results in humans. The ultimate goal: to help people like Brenda walk again.

Here is the original post:
Stem cell procedures for paralysis patients

iPSC model helps to better understand genetic lung/liver disease

By Stem Cell Medical Center

Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin (AAT) deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease.

The study, which appears in Stem Cell Reports, also found that liver cells derived from AAT deficient iPSCs are more sensitive to drugs that cause liver toxicity than liver cells derived from normal iPSCs. This finding may ultimately lead to new treatments for the condition.

IPSC's are derived from the donated skin or blood cells of adults and, with the reactivation of four genes, are reprogrammed back to an embryonic stem cell-like state. Like embryonic stem cells, iPSC can be differentiated toward any cell type in the body, but they do not require the use of embryos. Alpha-1 antitrypsin deficiency is a common genetic cause of both liver and lung disease affecting an estimated 3.4 million people worldwide.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) worked for several years in collaboration with Dr. Paul Gadue and his group from Children's Hospital of Philadelphia to create iPSC from patients with and without AAT deficiency. They then exposed these cells to certain growth factors in-vitro to cause them to turn into liver-like cells, in a process that mimics embryonic development. Then the researchers studied these "iPSC-hepatic cells" and found the diseased cells secrete AAT protein more slowly than normal cells. This finding demonstrated that the iPSC model recapitulates a critical aspect of the disease as it occurs in patients. AAT deficiency is caused by a mutation of a single DNA base. Correcting this single base back to the normal sequence fixed the abnormal secretion.

"We found that these corrected cells had a normal secretion kinetic when compared with their diseased, parental cells that are otherwise genetically identical except for this single DNA base," explained lead author Andrew A. Wilson, MD, assistant professor of medicine at Boston University School of Medicine and Director of the Alpha-1 Center at Bu and BMC.

They also found the diseased (AAT deficient) iPSC-liver cells were more sensitive to certain drugs (experience increased toxicity) than those from normal individuals. "This is important because it suggests that the livers of actual patients with this disease might be more sensitive in the same way," said Wilson, who is also a physician in pulmonary, critical care and allergy medicine at BMC.

According to Wilson, while some patients are often advised by their physicians to avoid these types of drugs, these recommendations are not based on solid scientific evidence. "This approach might now be used to generate that sort of evidence to guide clinical decisions," he added.

The researchers believe that studies using patient-derived stem cells will allow them to better understand how patients with AAT deficiency develop liver disease. "We hope that the insights we gain from these studies will result in the discovery of new potential treatments for affected patients in the near future," said Wilson.

Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.

Excerpt from:
iPSC model helps to better understand genetic lung/liver disease

Scripps Health Receives $7.6M Grant to Regrow Knee Cartilage

By Stem Cell Clinic

Dr. Darryl DLima. Photo courtesy of Scripps Health

Scripps Health announced today it has received a $7.6 million grant to study the repair and regeneration of knee cartilage, and the underlying bone defects and lesions caused by osteoarthritis.

The award from the California Institute for Regenerative Medicine will support ongoing stem cell research by the Shiley Center for Orthopedic Research and Education at Scripps Clinic.

The funding provided by CIRM is essential to the development and support of the research we are doing with regard to tissue regeneration at Scripps, said Dr. Darryl DLima, the Scripps Health director of orthopedic research. With this grant we plan to continue our progress in this field and move toward clinical trials within the next three years.

Scripps researchers are studying a cell therapy that combines stem cells with a natural scaffold made of water-based gels to support the repair of cartilage and bone defects. Such defects, if left untreated, are a major factor in contributing to early osteoarthritis in patients younger than 55.

Caused by the deterioration of cartilage between joints, osteoarthritis affects more than 27 million people in the United States, according to the U.S. Centers for Disease Control and Prevention.

Almost all current strategies to repair knee cartilage involve the removal of healthy cartilage and tissue around the lesion and the creation of artificial defects in the joint to facilitate further treatment or implantation. However, for younger patients with severe arthritis or impending arthritis, there is no treatment that can prevent, cure or even slow the progression of this disease.

Scientists with The Scripps Research Institute and Sanford-Burnham Medical Research Institute are assisting with the project.

City News Service

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

See the original post here:
Scripps Health Receives $7.6M Grant to Regrow Knee Cartilage

Possible progress against Parkinson's and good news for stem cell therapies

By Stem Cell Treatment

Brazilian researchers at D'OR Institute for Research and Education (IDOR) and Federal University of Rio de Janeiro (UFRJ) have taken what they describe as an important step toward using the implantation of stem cell-generated neurons as a treatment for Parkinson's disease. Using an FDA approved substance for treating stomach cancer, Rehen and colleagues were able to grow dopamine-producing neurons derived from embryonic stem cells that remained healthy and functional for as long as 15 months after implantation into mice, restoring motor function without forming tumors.

Parkinson's, which affect as many 10 million people in the world, is caused by a depletion of dopamine-producing neurons in the brain. Current treatments include medications and electrical implants in the brain which causes severe adverse effects over time and fail to prevent disease progression. Several studies have indicated that the transplantation of embryonic stem cells improves motor functions in animal models. However, until now, the procedure has shown to be unsafe, because of the risk of tumors upon transplantation.

To address this issue, the researchers tested for the first time to pre-treat undifferentiated mouse embryonic stem cells with mitomycin C, a drug already prescribed to treat cancer. The substance blocks the DNA replication and prevents the cells to multiply out of control.

The researchers used mice modeled for Parkinson's. The animals were separated in three groups. The first one, the control group, did not receive the stem cell implant. The second one, received the implant of stem cells which were not treated with mitomycin C and the third one received the mitomycin C treated cells.

After the injection of 50,000 untreated stem cells, the animals of the second group showed improvement in motor functions but all of them died between 3 and 7 weeks later. These animals also developed intracerebral tumors. In contrast, animals receiving the treated stem cells showed improvement of Parkinson's symptoms and survived until the end of the observation period of 12 weeks post-transplant with no tumors detected. Four of these mice were monitored for as long as 15 months with no signs of pathology.

Furthermore, the scientists have also shown that treating the stem cells with mitomycin C induced a four-fold increase in the release of dopamine after in vitro differentiation.

"This simple strategy of shortly exposing pluripotent stem cells to an anti-cancer drug turned the transplant safer, by eliminating the risk of tumor formation," says the leader of the study Stevens Rehen, Professor at UFRJ and researcher at IDOR.

The discovery, reported on April in the journal Frontiers in Cellular Neuroscience, could pave the way for researchers and physicians to propose a clinical trial using pluripotent stem cells treated with mitomycin C prior to transplant to treat Parkinson's patients and also other neurodegenerative conditions.

"Our technique with mitomycin C may speed the proposal of clinical trials with pluripotent cells to several human diseases," says Rehen. "It is the first step to make this kind of treatment with stem cells possible."

Story Source:

See original here:
Possible progress against Parkinson's and good news for stem cell therapies

UCSDs Stem Cell Break Through Could Lead to Treatment for Type-1 Diabetes

By Stem Cell Treatment

A UC San Diego student examines a bacteria culture. Photo courtesy UCSD

Researchers at the UC San Diego School of Medicine announced Thursdaytheyve discovered why its so hard to use stem cells to make liver and pancreatic cells, and their findings could lead to new treatments for diseases such astype-1 diabetes.

It turns out that the chromosomes in laboratory stem cells open slowly over time, in the same sequence that occurs during embryonic development. It isnt until certain chromosomal regions have reached the open state that they are able to respond to added growth factors and become liver or pancreatic cells, the researchers said.

Our ability to generate liver and pancreatic cells from stem cells has fallen behind the advances weve made for other cell types, said Dr. Maike Sander, a professor of pediatrics and cellular and molecular medicine, and director of the Pediatric Diabetes Research Center at UCSD.

So we havent yet been able to do things like test new drugs on stem cell-derived liver and pancreatic cells, Sander said. What we have learned is that if we want to make specific cells from stem cells, we need ways to predict how those cells and their chromosomes will respond to the growth factors.

Researchers have focused on stem cells for treating disease because they can be altered into hundreds of types of cells.

According to UCSD, it sometimes takes up to seven carefully orchestrated steps of adding certain growth factors at specific times to coax stem cells into the desired cell type.

Sander said the study found that the chromosomal regions that need to open before a stem cell can fully differentiate are linked to regions where there are variations in certain disease states. That means if a genetic variation in someones chromosomal region doesnt open at the right time, they could be more susceptible to a disease affecting that cell type.

Herteam is now working to further investigate what role, if any, the chromosomal regions and their variations play in diabetes.

Researchers with the University of Pennsylvania, Penn State University and Ludwig Institute for Cancer Research assisted with the study, funded by the National Institutes of Health, California Institute for Regenerative Medicine, the Helmsley Charitable Trust and Juvenile Diabetes Research Foundation.

Read more from the original source:
UCSDs Stem Cell Break Through Could Lead to Treatment for Type-1 Diabetes

→←